Investigating the Miracle Biologic Lecanemab for Alzheimer's Disease - Part 3
Lecanemab’s harms evidence base from the Phase II trial
Following on from our previous two posts
We look further into the “Core” Phase II study 201, which enrolled 856 people with early Alzheimer’s Disease (AD). Of these, 180 went on to participate in the OLE (Open-Label…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.